689 related articles for article (PubMed ID: 28978555)
1. Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13.
Davis C; Naci H; Gurpinar E; Poplavska E; Pinto A; Aggarwal A
BMJ; 2017 Oct; 359():j4530. PubMed ID: 28978555
[No Abstract] [Full Text] [Related]
2. Assessment of Food and Drug Administration- and European Medicines Agency-Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life: A Systematic Review.
Arciero V; Delos Santos S; Koshy L; Rahmadian A; Saluja R; Everest L; Parmar A; Chan KKW
JAMA Netw Open; 2021 Feb; 4(2):e2033004. PubMed ID: 33570573
[TBL] [Abstract][Full Text] [Related]
3. Publicly accessible evidence of health-related quality of life benefits associated with cancer drugs approved by the European Medicines Agency between 2009 and 2015.
Grössmann N; Robausch M; Rothschedl E; Wild C; Simon J
Eur J Cancer; 2020 Apr; 129():23-31. PubMed ID: 32120272
[TBL] [Abstract][Full Text] [Related]
4. Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States.
Salcher-Konrad M; Naci H; Davis C
Milbank Q; 2020 Dec; 98(4):1219-1256. PubMed ID: 33021339
[TBL] [Abstract][Full Text] [Related]
5. Assessing the benefit of cancer drugs approved by the European Medicines Agency using the European Society for Medical Oncology Magnitude of Clinical Benefit Scale over time.
Thomson S; Witzke N; Gyawali B; Delos Santos S; Udayakumar S; Cardone C; Cheung MC; Chan KKW
Eur J Cancer; 2021 Jun; 150():203-210. PubMed ID: 33932727
[TBL] [Abstract][Full Text] [Related]
6. Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration.
Tibau A; Molto C; Ocana A; Templeton AJ; Del Carpio LP; Del Paggio JC; Barnadas A; Booth CM; Amir E
J Natl Cancer Inst; 2018 May; 110(5):486-492. PubMed ID: 29244173
[TBL] [Abstract][Full Text] [Related]
7. Twelve years of European cancer drug approval-a systematic investigation of the 'magnitude of clinical benefit'.
Grössmann N; Wolf S; Rothschedl E; Wild C
ESMO Open; 2021 Jun; 6(3):100166. PubMed ID: 34087744
[TBL] [Abstract][Full Text] [Related]
8. A Qualitative Study on the Differences Between Trial Populations and the Approved Therapeutic Indications of Antineoplastic Agents by 3 Regulatory Agencies From 2010 to 2018.
Sumi E; Asada R; Lu Y; Ito-Ihara T; Grimes KV
Clin Ther; 2020 Feb; 42(2):305-320.e0. PubMed ID: 32008723
[TBL] [Abstract][Full Text] [Related]
9. Clinical benefit and cost of breakthrough cancer drugs approved by the US Food and Drug Administration.
Molto C; Hwang TJ; Borrell M; Andres M; Gich I; Barnadas A; Amir E; Kesselheim AS; Tibau A
Cancer; 2020 Oct; 126(19):4390-4399. PubMed ID: 32697362
[TBL] [Abstract][Full Text] [Related]
10. Five years of EMA-approved systemic cancer therapies for solid tumours-a comparison of two thresholds for meaningful clinical benefit.
Grössmann N; Del Paggio JC; Wolf S; Sullivan R; Booth CM; Rosian K; Emprechtinger R; Wild C
Eur J Cancer; 2017 Sep; 82():66-71. PubMed ID: 28648700
[TBL] [Abstract][Full Text] [Related]
11. Design characteristics, risk of bias, and reporting of randomised controlled trials supporting approvals of cancer drugs by European Medicines Agency, 2014-16: cross sectional analysis.
Naci H; Davis C; Savović J; Higgins JPT; Sterne JAC; Gyawali B; Romo-Sandoval X; Handley N; Booth CM
BMJ; 2019 Sep; 366():l5221. PubMed ID: 31533922
[TBL] [Abstract][Full Text] [Related]
12. [New drugs in oncology--features of clinical trials for market authorisation and arguments for the rapid implementation of independent clinical trials following approval].
Ludwig WD; Schott G
Onkologie; 2013; 36 Suppl 2():17-22. PubMed ID: 23549032
[TBL] [Abstract][Full Text] [Related]
13. Monitoring evidence on overall survival benefits of anticancer drugs approved by the European Medicines Agency between 2009 and 2015.
Grössmann N; Robausch M; Rosian K; Wild C; Simon J
Eur J Cancer; 2019 Mar; 110():1-7. PubMed ID: 30735832
[TBL] [Abstract][Full Text] [Related]
14. The ESMO-Magnitude of Clinical Benefit Scale for novel oncology drugs: correspondence with three years of reimbursement decisions in Israel.
Hammerman A; Greenberg-Dotan S; Feldhamer I; Birnbaum Y; Cherny NI
Expert Rev Pharmacoecon Outcomes Res; 2018 Feb; 18(1):119-122. PubMed ID: 28617621
[TBL] [Abstract][Full Text] [Related]
15. Pre-approval and post-approval availability of evidence and clinical benefit of conditionally approved cancer drugs in Europe: A comparison with standard approved cancer drugs.
Bloem LT; Bot RE; Mantel-Teeuwisse AK; van der Elst ME; Sonke GS; Klungel OH; Leufkens HGM; Hoekman J
Br J Clin Pharmacol; 2022 May; 88(5):2169-2179. PubMed ID: 34779004
[TBL] [Abstract][Full Text] [Related]
16. Overall Survival Benefits of Cancer Drugs Approved in China From 2005 to 2020.
Zhang Y; Naci H; Wagner AK; Xu Z; Yang Y; Zhu J; Ji J; Shi L; Guan X
JAMA Netw Open; 2022 Aug; 5(8):e2225973. PubMed ID: 35947385
[TBL] [Abstract][Full Text] [Related]
17. A Review of Labeling Based on Patient-Reported Outcome Endpoints for New Oncology Drugs Approved by the European Medicines Agency (2017-2021).
Gnanasakthy A; Levy C; Norcross L; Doward L; Winnette R
Value Health; 2023 Jun; 26(6):893-901. PubMed ID: 36746305
[TBL] [Abstract][Full Text] [Related]
18. Clinical Value of Molecular Targets and FDA-Approved Genome-Targeted Cancer Therapies.
Tibau A; Hwang TJ; Molto C; Avorn J; Kesselheim AS
JAMA Oncol; 2024 May; 10(5):634-641. PubMed ID: 38573645
[TBL] [Abstract][Full Text] [Related]
19. Overall survival benefits of cancer drugs initially approved by the US Food and Drug Administration on the basis of immature survival data: a retrospective analysis.
Naci H; Zhang Y; Woloshin S; Guan X; Xu Z; Wagner AK
Lancet Oncol; 2024 Jun; 25(6):760-769. PubMed ID: 38754451
[TBL] [Abstract][Full Text] [Related]
20. Potential negative impact of reputed regulators' decisions on the approval status of new cancer drugs in Latin American countries: A descriptive analysis.
Durán CE; Cañás M; Urtasun M; Elseviers M; Vander Stichele R; Christiaens T
PLoS One; 2021; 16(7):e0254585. PubMed ID: 34255795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]